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Abstract
Background: In this study, we retrospectively analyzed the relationship between headache recurrence and
serotonin 5-HT1B/1D receptor occupancy (Φ1B and Φ1D). Triptans marketed in Japan (sumatriptan, zolmitriptan,
eletriptan, rizatriptan, naratriptan) were investigated.
Methods: Receptor occupancies were calculated from both the pharmacokinetic and pharmacodynamic data of
triptans. We examined the relationships between recurrence rate and elimination half-lives, and Ф1B and Ф1D, as
calculated from the time-course of plasma drug concentration obtained from other studies. The time until Ф1B and
Ф1D became 50 % or less, 40 % or less, and 30 % or less was calculated as duration time to examine the
relationship with recurrence rate.
Results: For Ф1B, eletriptan remained at a low level. For Ф1D, it was indicated that all triptans obtained an
occupancy of 80 % or higher at maximum. For all items, though recurrence tended to be lower along with longer
half-life, no significant statistical correlation was found. For both Ф1B and Ф1D, the recurrence rate tended to be
lower as the duration became longer. In addition, a significant correlation was observed for Ф1D (p < 0.05). For
clarifying the Ф value and time period most closely correlated with recurrence rate, recurrence and Ф1B and Ф1D
at 6, 12, and 18 h after administration were calculated. The most significant correlation was observed between
recurrence rate and Ф1D at 12 h after administration (p < 0.01).
Conclusions: As an index for evaluating headache recurrence following triptan administration, recurrence rate and
Ф1D value at 12 h after administration were found to be most closely correlated and useful for analysis. Our results
indicate that headache recurrence inhibition can be evaluated using these values.
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Background
Triptans are serotonin 5-HT1B/1D agonists frequently
used as migraine-abortive drugs. Presently, 5 different
triptans are marketed in Japan, though lack of informa-
tion is a problem for selection of the proper drug and
that choice is largely dependent on only the experience
of the attending physician. Even in the Japanese ‘Prac-
tical guidelines for chronic headaches’, it is noted that
the triptans vary in regard to their pharmacological
properties and therapeutic effects different with individ-
ual patients. For choice of the rational triptan, the only
description states that the proper choice has not yet
been elucidated, as there have been few closed studies
with a satisfactory number of subjects [1]. Furthermore,
it has been pointed out that the headache sometimes
returned even after administration. Thus, it is considered
indispensable to establish a theoretical dosage regimen
for inhibiting recurrence. Differences in triptan’s thera-
peutic effects among individuals and drug characteris-
tics, as well as lack of evidence for selecting a suitable
drug for each patient are problems to be resolved. And
it is important to establish an index for quantitative
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evaluation of the pharmacological and clinical effects of
triptans.
Concerning headache recurrence following triptan ad-
ministration, relationships between recurrence and elim-
ination half-lives of plasma drug concentrations have been
reported in other countries [2], whereas nearly nothing
has been presented on this subject in Japan. Meanwhile,
our department performed analysis of the clinical effects
of triptans (headache relief rate) by focusing on serotonin
5-HT1B and 5-HT1D receptor occupancies (Ф), and we
found that the parameter (AФ • AUCФ) of the area under
the time curve of Ф (AUCФ) until the efficacy evaluation
time point after correction by the velocity factor AФ
(Фmax/Tmax) could serve as an index to correct the differ-
ences between drug and formulations, and uniformly
evaluate them [3, 4].
In the present study, we performed a theoretical evalu-
ation of headache recurrence following triptan administra-
tion in Japanese based on serotonin 5-HT1B and 5-HT1D
receptor occupancies.
Methods
Collection of pharmacokinetic and pharmacodynamic
parameters
Triptans marketed in Japan (sumatriptan, zolmitriptan,
eletriptan, rizatriptan, naratriptan) were investigated.
Data regarding pharmacokinetic and pharmacodynamics
parameters, and headache recurrence rate (referred to as
recurrence rate hereinafter) were obtained from pub-
lished studies. In Japan, data obtained from various
clinical trials performed domestically are included in the
clinical data package for new drug registration, while
drug properties and clinical trial results were extracted
from those downloadable from the website of the regu-
latory authority the Pharmaceuticals and Medical De-
vices Agency (PMDA) (http://www.pmda.go.jp). When
data were not available at that website, they were collected
from published studies. For pharmacokinetic parameters,
data for plasma drug concentration following adminis-
tration of each drug, plasma elimination half-life, plasma
unbound protein fraction, and the presence of active me-
tabolite were collected from clinical trial results. For
pharmacodynamics parameters, the dissociation constant
Ki values for the serotonin 5-HT1B and 5-HT1D re-
ceptors were obtained.
Calculation of serotonin 5-HT1B and 5-HT1D receptor
occupancies
On the basis of the receptor occupancy theory, the time-
course changes of serotonin 5-HT1B and 5-HT1D recep-
tor occupancies Ф (Ф1B and Ф1D) of the triptans were
calculated.
Triptan can be classified into two types. One is only
the unchanged drug has pharmacological effect, and the
other is both of unchanged drug and active metabolite
has pharmacological effect.
1) When only the unchanged drug was involved in
drug efficacy:
The plasma concentration of the unbound drug (Cf )
after a single administration of the drug in Japanese sub-
jects, and the dissociation constant Ki (Ki1B and Ki1D) of
serotonin 5-HT1B and 5-HT1D were substituted in equa-
tion (1) to calculate the time course of Ф1B and Ф1D.
Φ %ð Þ ¼ Cf
Cf þ Ki  100 ð1Þ
2) When only one kind of active metabolite was
present:
The changes in Ф1B and Ф1D were calculated by sub-
stituting the plasma unbound drug concentrations (Cf
1
and Cf
2) of the unchanged drug and active metabolite
after a time of single-dose administration, and the dis-





2) in equation (2).
Φ %ð Þ ¼ C
1
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Relationship between headache recurrence and serotonin
5-HT1B and 5-HT1D receptor occupancies
The relationships between time-course changes of Ф1B
and Ф1D were obtained, and headache recurrence rate
(recurrence rate) were examined. For the definition of re-
currence, migraine pain was rated as follows: grade 0, no
pain; grade 1, mild pain; grade 2, moderate pain; grade 3,
severe pain. The patients whose headache improved from
grade 3 or 2 to grade 1 or 0 at 1-4 h after initial
administration but returned to grade 3 or grade 2 within
24 h after administration were regarded as having recur-
rence. Data for patients who met the requirements were
collected from clinical trial data published in the appli-
cation summary and published reports. The headache re-
currence rate (recurrence rate) was obtained by dividing
the number of subjects with recurrence by the number of
those with relief. Then the following items (1-3) were
examined.
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(1)Relationships between headache recurrence rate
(recurrence rate) and elimination half-lives of plasma
drug concentrations, Ф1B, and Ф1D.
(2)Relationships between headache recurrence rate
(recurrence rate) and duration time of Ф1B and Ф1D.
(3)Relationships between headache recurrence rate
(recurrence rate) and Ф1B and Ф1D at 6, 12, and
18 h after administration.
Results
Extraction of pharmacokinetic and pharmacodynamics
parameters for drugs and recurrence rate
Table 1 shows the generic name, formulation, elimin-
ation half-life (t1/2), molecular weight (MW), plasma un-
bound fraction (fu), and Ki values for the serotonin 5-
HT1B and 5-HT1D receptors. For zolmitriptan, data for
both the unchanged drug and active metabolite were
collected, as an active metabolite that seemingly affected
efficacy was considered to be present.
Table 2 shows the dose and formulation for single-
dose administration, and recurrence rate for each of the
5 triptans. The recurrence rate varied depending on the
drug and formulation.
Time course of Ф after administration of each triptan
Changes in plasma drug concentrations after a single-
dose administration for 5 triptans in Japanese subjects
are shown in Fig. 1. These data included not only usual
but also clinical dose data by which evaluation of recur-
rence rate was reported. Changes in serotonin 5-HT1B
and 5-HT1D receptor occupancies (Ф1B and Ф1D) at the
time of usual-dose administration calculated from the
pharmacokinetic and pharmacodynamic parameters are
shown in Fig. 2.
For Ф1B, eletriptan remained at a low level. For Ф1D, it
was indicated that all triptans obtained an occupancy of
80 % or higher at maximum. Moreover, the injectable
form of sumatriptan showed a quicker occupancy de-
cline than the other triptans for Ф1B and Ф1D.
Relationship with recurrence rate
Relationship between recurrence rate and elimination
half-lives of plasma drug concentrations Ф1B and Ф1D
The relationships between recurrence rate and elimin-
ation half-lives, and Ф1B and Ф1D, as calculated from the
time-course of plasma drug concentration obtained from
other studies, are shown in Fig. 3. In our investigation of
elimination half-life, zolmitriptan with active metabolites
was excluded, as it could not be examined only on the
basis of half-life in an unchanged drug.
For all items, though recurrence tended to be lower
along with longer half-life, no significant statistical cor-
relation was found.
Relationship between recurrence rate and duration
time of Ф
The time until Ф1B and Ф1D became 50 % or less, 40 %
or less, and 30 % or less was calculated as duration time
to examine the relationship with recurrence rate. Table 3
shows the calculated duration time of Ф1B and Ф1D.
Figure 4 shows the relationship with the duration time
of Ф1B and Ф1D.
For both Ф1B and Ф1D, the recurrence rate tended to
be lower as the duration became longer. In addition, a
significant correlation was observed for Ф1D.
Relationship between recurrence rate and Ф1B and Ф1D at
6, 12, and 18 h after administration
For clarifying the Ф value and time period most closely
correlated with recurrence rate, recurrence and Ф1B and
Ф1D at 6, 12, and 18 h after administration were
calculated. Table 4 shows calculated Ф1B and Ф1D values
at 6, 12, and 18 h after administration.
The relationships between recurrence rate and Ф1B
and Ф1D at each time point are shown in Fig. 5.
For Ф1B, the aspect differed depending on each time
point, while for Ф1D, the recurrence rate tended to be
lower when Ф1D was larger. Significant correlations with
recurrence rate were observed at 12, and 18 h after ad-
ministration. Notably, the most significant correlation
Table 1 Pharmacokinetic and pharmacodynamic parameters of triptans [12, 15, 19–24]
Drug (formulation) t1/2
(hr)
MW fu Ki (nM)
5-HT1B 5-HT1D
Sumatriptan (subcutaneous injection) [19] 1.46 295.40 0.66 12.59 12.59
Zolmitriptan (oral tablet) Unchanged drug [12, 20] 2.40 287.30 0.75 a6.31 a2.51
Active metabolite [12, 20, 21] 2.35 273.36 0.75 a1.58 a0.50
Eletriptan (oral tablet) [22] 3.20 382.52 0.13 10.0 1.15
Rizatriptan (oral tablet) [23, 24] 1.60 269.35 0.86 7.24 2.34
Naratriptan (oral tablet) [15] 5.05 335.47 0.71 2.24 2.30
aCalculated from radioligand test
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was observed between recurrence rate and Ф1D at 12 h
after administration.
Discussion
During migraine treatment, a headache sometimes returns
after remission achieved by administration of triptans,
which are serotonin 5-HT1B/1D receptor agonists. Accord-
ingly it is indispensable to establish information related to
proper use to prevent recurrence. In the present study, we
performed theoretical evaluations for establishing proper
use by calculating serotonin 5-HTIB and 5-HT1D receptor
occupancies, and examined their relationship with head-
ache recurrence.
Drug action is determined by drug concentration in the
region of the site of action and binding to the target recep-
tor. When drug action is elicited by a specific target recep-
tor, it is important to kinetically clarify the relationship
between them. In our previous study, we have reported
Table 2 Japanese headache recurrence rate data [12, 24–27]
Drug Dose (mg/time) Formulation Recurrence rate (%)
Sumatriptan [25] 3 Subcutaneous injection 54.8 [n = 31]
Zolmitriptan [12] 2.5 Oral tablet 13.0 [n = 30]
Eletriptan [26] 20 Oral tablet 10.0 [n = 51]
40 Oral tablet 17.0 [n = 52]
80 Oral tablet 14.0 [n = 59]
Rizatriptan [24] 10 Oral tablet 31.7 [n = 41]
10 RPD oral tablet 46.9 [n = 32]
Naratritpan [27] 1 Oral tablet 24.3 [n = 74]
2.5 Oral tablet 11.9 [n = 84]
RPD rapid dissolution
Fig. 1 Changes in plasma drug concentrations after a single-dose administration in Japanese subjects. (SC: subcutaneous injection, Tab: oral
tablet, RPD Tab: rapid dissolution oral tablet, solid line: usual-dose in Japan)
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that receptor occupancy is useful for theoretical evaluation
of the standard therapeutic doses of various groups of
drugs, and a more appropriate index for estimating drug
action than dose or blood concentration [5–10].
For collecting pharmacokinetic parameters and recur-
rence data, we selected only clinical trials that used Japa-
nese subjects. Regarding pharmacodynamic parameters,
we collected Ki values that showed an affinity to the
serotonin 5-HT1B and 5-HT1D receptors based on
pharmaceutical interview forms and literature from new
drug application data summaries. Only for zolmitriptan,
the Ki value could not be obtained from literature. How-
ever, it was reported that the Ki value was equivalent to
the IC50 value of the radioactive ligand displacement
trial [11], thus we used it as substitute for the Ki value
in our analysis. Furthermore, since one kind of active
Fig. 2 Changes in Ф1B and Ф1D at the time of usual-dose administration. (SC: subcutaneous injection, Tab: oral tablet, solid line: usual-dose
in Japan)
Fig. 3 Relationships between headache recurrence rate and elimination half-lives of plasma drug concentration, Φ1B and Φ1D
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metabolite considered to affect efficacy was present for
zolmitriptan, we collected data regarding the unchanged
drug and active metabolite for the present analysis.
In this study, therefore using the pharmacokinetic data of
a Japanese subject, it was necessary to examine the data for
clinical trials in Japan. However, the information that has
been published in clinical trials of Japanese was less. In the
future, in order to analyze in more detail, it is required to
include more data for clinical trials.
The definition of recurrence was found to vary among the
clinical trials examined. Notably, the method for determining
the time period until headache relief following the initial ad-
ministration differed. In the present analysis, for comparing
recurrence rates among the 5 triptans according to the same
definition, we used the following: the ratio of patients who
had headache relief 1-4 h after the initial administration but
had headache return within 24 h after administration.
In clinical trials of zolmitriptan, there was no differ-
ence found in regard to recurrence rate between patients
who had headache relief 2 h after administration and
those who had relief 4 h after administration [12]. Ac-
cordingly, we employed that in our analysis based on the
assumption that the method for determining the time
period until headache relief may not cause a dispersion
in recurrence rate. In the future, it is expected that ana-
lysis precision might be further improved if comparisons
can be made by using data collected according to a uni-
fied definition of recurrence. Using our definition to
analyze clinical trial data of Japanese patients we
obtained recurrence rates for sumatriptan (3 mg sub-
cutaneous injectable) (headache relief at 1 h after
administration), zolmitriptan (2.5-mg tablets), eletriptan
(20-, 40-, 80-mg tablets), rizatriptan (10-mg tablets),
RPD (10-mg tablets) (headache relief at 2 h after
administration), and naratriptan 1- and 2.5-mg tablets
(headache relief at 4 h after administration). The rate
was relatively low for eletriptan and naratriptan, whereas
it was high for rizatriptan. Also, the injectable form had



















Zolmitriptan 2.5 (oral tablet) 9.6 11.3 13.1
Eletriptan 20 (oral tablet) 1.4 3.1 6.1
40 (oral tablet) 6.7 8.9 11.1
80 (oral tablet) 11 12.8 14.9
Rizatriptan 10 (oral tablet) 8 9.6 11.3
10 (RPD oral tablet) 7.2 8.1 9.2
Naratritpan 1 (oral tablet) 7.2 9.8 12.7













became 30 % or
less
(hr)
Sumatriptan 3 (subcutaneous injection) 1.3 2.4 2.5
Zolmitriptan 2.5 (oral tablet) 14.6 16.6 18.6
Eletriptan 20 (oral tablet) 10.9 12.8 14.9
40 (oral tablet) 18.3 21.2 24
80 (oral tablet) 22.9 26.7 31.1
Rizatriptan 10 (oral tablet) 12.2 13.8 15.5
10 (RPD oral tablet) 9.3 10.1 10.8
Naratritpan 1 (oral tablet) 7.2 9.7 12.7
2.5 (oral tablet) 12.4 15.6 17.9
RPD rapid dissolution
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a higher rate of recurrence than tablets. Thus, our find-
ings clarified that recurrence rate varied among the kind
and administered form of the drugs.
In the present analysis, the drug concentration near
the subject receptor was speculated to be at the same
level as that of the plasma unbound drug concentration.
Triptans act on the serotonin 5-HT1B and 5-HT1D re-
ceptors, and they are thought to work in three main
ways: 1) peripheral inhibition of release of vasodilator
neuropeptides; 2) modulation of second-order neurons
centrally in the trigeminocervical pathway; and 3) vaso-
constriction [13]. There are no studies that performed
direct measurements of drug concentration near those
receptors, thus we speculate that the drug transits to
plasma after administration and the unbound form from
plasma protein penetrates through the vascular wall to
reach the action site [14]. Smatriptan and naratriptan
especially are scarcely passed through the blood–brain
barrier (BBB) and were weakly distributed in the central
nervous system [15, 16]. However, they elicited the same
therapeutic effect for migraine as other triptans. Further-
more, it is reported that triptans also acted on 5-HT1B/
1D receptors in the trigeminal and dorsal root ganglion
cells where BBB was lacked rather than in the sites with
BBB in the trigeminovascular system [17]. Accordingly,
we did not take concentration in other tissues such as
the brain into consideration. As certain findings could
be obtained on the basis of these speculations, we con-
sidered that they had some validity. More detailed ana-
lysis would be possible if the actual concentration near
the receptors could be measured at the time of adminis-
tration in human subjects.
On the basis of data collected regarding changes in
plasma drug concentration in Japanese patients, as well
as pharmacokinetic and pharmacodynamics parameters,
we calculated the time-course changes of receptor occu-
pancies (Ф1B and Ф1D). As the dose varied depending on
the kind of triptan, it was considered difficult to make a
Fig. 4 Relationships between headache recurrence and duration time of Φ1B and Φ1D
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quantitative evaluation on the basis of plasma drug con-
centration. However, that of recurrence rate using Ф was
considered possible and applicable as a unified index
irrespective of drug kind. For Ф1B, eletriptan maintained
a low level in whole, whereas for Ф1D, it was observed
that all of the tested triptans attained an occupancy of
80 % or higher at maximum. As compared to the other
triptans, sumatriptan injectable had a short half-life of
plasma drug concentration, and showed a quicker de-
cline of occupancy for both Ф1B and Ф1D.
As for headache recurrence following triptan administra-
tion, a study conducted with western subjects noted that a
certain relationship could be observed between elimination
half-life and recurrence rate [2]. Thus, we first investigated
the relationship between recurrence rate and elimination
half-life of plasma drug concentration. For both, longer
half-life was related to lower recurrence rate, though the
differences were not statistically significant. In addition, the
drug which has an active metabolite like zolmitriptan, could
not be compared with other drugs based on elimination
half-life of plasma drug concentration.
In Japan, there was a report which considered the rela-
tionship between efficacy time of triptans and recurrence
rate [18]. Thus, we examined the relationship between
recurrence rate and duration time of Ф after administra-
tion. As the Ф1B value of eletriptan was maintained at
the relatively low level of 53.1 % at a maximum, our ana-
lysis was performed by setting the index of duration time
as the time until Ф1B and Ф1D became 50 % or less,
40 % or less, and 30 % or less. For Ф1B, no statistically
significant correlation could be obtained. For Ф1D, recur-
rence rate tended to be lower as duration time was
longer, which showed a statistically significant correl-
ation. Thus, it considered likely that the time required to
maintain Ф1D higher than a certain level might have an
effect on recurrence rate.
Furthermore, for elucidating the Ф value and time period
most closely correlated with recurrence rate, we examined
the relationship between recurrence rate and Ф at predeter-
mined time points after administration in subjects who had
headache recurrence within 24 h after administration.
However, for plasma drug concentration, time-course data
up to 24 h after administration could not be calculated, as
they were not available. Accordingly, we focused on Ф until
6-18 h after administration, and analyzed the relationship
between recurrence rate and Ф every 6 h. No correlation




6 h after administration
(%)
12 h after administration
(%)
18 h after administration
(%)
Sumatriptan 3 (subcutaneous injection) 0 0 0
Zolmitriptan 2.5 (oral tablet) 76.3 36.1 3.3
Eletriptan 20 (oral tablet) 25.3 8.7 1.5
40 (oral tablet) 52.9 25.7 11.4
80 (oral tablet) 75.7 43.6 20.7
Rizatriptan 10 (oral tablet) 66.9 25.8 0
10 (RPD oral tablet) 62.9 5.7 0
Naratritpan 1 (oral tablet) 54.3 32.1 10




6 h after administration
(%)
12 h after administration
(%)
18 h after administration
(%)
Sumatriptan 3 (subcutaneous injection) 0 0 0
Zolmitriptan 2.5 (oral tablet) 90.7 63.1 33
Eletriptan 20 (oral tablet) 74.3 44.3 14.7
40 (oral tablet) 90.7 75 50.7
80 (oral tablet) 96.4 87.1 67.1
Rizatriptan 10 (oral tablet) 86.2 51.8 15
10 (RPD oral tablet) 83.6 16.4 0
Naratritpan 1 (oral tablet) 54.3 30.3 11.4
2.5 (oral tablet) 77.8 57 29.3
RPD rapid dissolution
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was found between Ф1B and recurrence rate, whereas a sig-
nificant correlation was observed between Ф1D and recur-
rence rate, with the most notable at 12 h after
administration. On the basis of these findings, it is sug-
gested that higher Ф1D at 12 h after administration is re-
lated to lower recurrence rate.
Conclusions
Based on our findings in this study of receptor occu-
pancy, it is suggested that Ф1D exerts a greater effect on
headache recurrence rate after triptan administration in
Japanese subjects as compared to Ф1B and that recur-
rence may be inhibited to a greater degree when Ф1D is
maintained at a higher level. Notably, as an index for
evaluating headache recurrence following triptan admin-
istration, recurrence rate and Ф1D value at 12 h after
administration were found to be most closely correlated
and useful for analysis. Our results indicate that head-
ache recurrence inhibition can be evaluated using these
values.
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